Fulgent Genetics, Inc.
No SEC Form 4 filings for $FLGT in the last 30 days.
See all $FLGT insider activity →Fulgent Genetics will host a live call on its third-quarter results at 4:30 p.m. ET on Nov. 5, accessible via its Investor Relations website. The company offers lab services and is developing cancer treatments, aiming to become a precision medicine company. An audio replay will be available post-call.
Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.
Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FLGT (Fulgent Genetics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent FLGT coverage spans financial news, earnings and insider activity.
This is a pre-earnings scheduling notice, so the main tradable element is positioning into the Nov. 5 Q3 release and call.
Guidance cut tied to revenue-cycle delays is the near-term earnings risk, partially offset by sequential growth and acquisition integration.
Guidance cut tied to revenue-cycle transition delays is the key near-term driver, alongside ongoing cash burn and buyback activity.
Insider selling is a modest negative signal, but this specific Form 4 provides limited fundamental information without a 10b5-1 plan or stated reason.
Insider selling is a modest negative signal, but this specific Form 4 provides limited fundamental information without a 10b5-1 plan or other context.
AlphAI scores every news story that mentions FLGT with an AI model for sentiment and relevance, and aggregates insider trades from Fulgent Genetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fulgent Genetics will host a live call on its third-quarter results at 4:30 p.m. ET on Nov. 5, accessible via its Investor Relations website. The company offers lab services and is developing cancer treatments, aiming to become a precision medicine company. An audio replay will be available post-call.
1 min readFulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.
7 min readFulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of
6 min readXie Jian (President and COO) sold 2,146 shares of Fulgent Genetics, Inc. (FLGT) at $17.89 on 2026-06-02.
2 min readGao Hanlin (Chief Scientific Officer) sold 1,688 shares of Fulgent Genetics, Inc. (FLGT) at $17.89 on 2026-06-02.
2 min readFulgent Genetics has significantly expanded its infertility next-generation sequencing (NGS) panels, now covering 143 genes for females and 163 genes for males. The company recommends combining these expanded panels with BeaconCarrierScreening for a thorough reproductive health assessment. This enhancement aims to provide more comprehensive genetic insights for couples facing fertility challenges.
2 min readFulgent Genetics' CFO and Treasurer, Paul Kim, had 2,747 shares of common stock withheld on April 26, 2026, to cover tax obligations arising from the vesting of restricted stock units. This was a routine tax-related disposition, not an open-market sale, and the shares were valued at $16.31 each. Following this transaction, Kim continues to hold a substantial 365,800 shares of Fulgent common stock.
2 min readJian Xie, President and COO of Fulgent Genetics (FLGT), reported a routine tax-related disposition of 4,361 common shares at $16.31 per share. This withholding was to satisfy tax obligations arising from the vesting of restricted stock units (RSUs) assumed through a prior merger. Following this transaction, Xie directly holds 370,952 common shares, with an additional 220,816 shares held indirectly by The Hsieh Family Dynasty Trust.
2 min readFulgent Genetics (FLGT) plans to acquire assets from Bako Diagnostics and StrataDx for approximately $55.5 million, using existing cash reserves. This strategic move, expected to finalize in the first half of 2026, aims to enhance Fulgent's diagnostic capabilities and expand its laboratory network. Despite financial challenges like declining revenue growth and insider selling, the company maintains strong financial health and liquidity, though investors are advised to exercise caution.
4 min readImage source: The Motley Fool.Friday, November 7, 2025 at 2:56 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min read
